Related Experiment Video
Updated: May 5, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
Leandro Cerchietti1, John P Leonard
11Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY.
Abstract:
Diffuse large B-cell lymphoma, the most common lymphoma subtype, is curable in the majority of patients. However, one of the greatest unmet needs in lymphoma treatment remains novel approaches to prevent relapsed or refractory disease. Genomic profiling has provided important prognostic information that is being used in the development of novel therapeutic strategies currently in clinical trials. It is clear, however, that epigenetic alterations provide an additional series of targets that can be pharmacologically modified and offer great potential to improving patient outcomes. Greater understanding of this area is providing important new insights that are now being explored in the clinical setting. Demethylating agents and drugs that disrupt histone modifiers are in early clinical trials with promising results, and other approaches targeting epigenetic pathways are in active preclinical and early clinical development.
Insights
Novel epigenetic therapies show promise for treating relapsed or refractory diffuse large B-cell lymphoma. Targeting epigenetic alterations offers new avenues to improve patient outcomes in this common lymphoma subtype.
Area of Science:
- Oncology
- Hematology
- Epigenetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, with most patients curable.
- A significant unmet need exists for novel treatments to prevent relapsed or refractory DLBCL.
- Genomic profiling has informed prognostic understanding and therapeutic strategies.
Purpose of the Study:
- To explore the potential of epigenetic alterations as therapeutic targets in DLBCL.
- To highlight emerging epigenetic strategies for improving patient outcomes in lymphoma.
Main Methods:
- Review of current research on epigenetic alterations in DLBCL.
- Analysis of early clinical trials involving demethylating agents and histone modifier inhibitors.
- Exploration of preclinical and early clinical development of other epigenetic pathway-targeting approaches.
Main Results:
- Epigenetic alterations represent a promising area for pharmacological intervention in DLBCL.
- Demethylating agents and histone modifier drugs are in early clinical trials with encouraging outcomes.
- Various other epigenetic-targeting strategies are under active preclinical and early clinical investigation.
Conclusions:
- Epigenetic modifications offer a new frontier for developing novel DLBCL therapies.
- Targeting epigenetic pathways holds significant potential for improving outcomes in relapsed or refractory DLBCL.
- Ongoing research and clinical trials are exploring these promising therapeutic avenues.
More Related Videos
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
24:02The ChroP Approach Combines ChIP and Mass Spectrometry to Dissect Locus-specific Proteomic Landscapes of Chromatin
Published on: April 11, 2014
